ARCA Biopharma
ABIO

Ticker changed

ABIO changed its ticker symbol to ORKA

See ORKA stock details

About: ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

Employees: 5

Healthcare In Vitro & In Vivo Diagnostic Substances

Financial journalist opinion

ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

The combined company will operate as “Oruka Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “ORKA” effective Tuesday, September 3, 2024 The combined company will operate as “Oruka Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “ORKA” effective Tuesday, September 3, 2024

ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

WESTMINSTER, Colo., Aug. 26, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced an update to the previously announced final amount of the special cash dividend (the “Special Dividend”), which will now equal $1.613 per share of ARCA's common stock, payable on August 28, 2024, to ARCA's stockholders of record as of August 26, 2024. The Special Dividend was declared by ARCA's Board of Directors on August 16, 2024, in connection with the previously announced merger (the “Merger”) with Oruka Therapeutics, Inc. (“Oruka”), pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the “Merger Agreement”). The exact amount of the Special Dividend was calculated in accordance with the Merger Agreement and based on ARCA's reasonable, good faith approximation of the amount by which ARCA's net cash, as determined prior to the closing of the Merger, will exceed $5,000,000.

ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

WESTMINSTER, Colo., Aug. 23, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced that its Board of Directors (the “Board”) has approved a reverse stock split of ARCA's common stock at a ratio of 1-for-12. ARCA's common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Global Market on September 3, 2024, under the new name Oruka Therapeutics, Inc. and under the new symbol “ORKA” following the anticipated closing of the merger with Oruka Therapeutics, Inc. (the “Merger”), with a new CUSIP number 687604108 and ISIN number US6876041087.

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics

Special dividend estimated to be $1.59 per share Payment of special dividend conditioned upon ARCA stockholder approval of the Proposed Merger with Oruka WESTMINSTER, Colo., Aug. 16, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced that its Board of Directors has declared a special cash dividend (the “Special Dividend”) in connection with the previously announced merger (the “Merger”) with Oruka Therapeutics, Inc. (“Oruka”) pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the “Merger Agreement”).

ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics

ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., Aug. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2024 financial results and provided a corporate update.

ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Shareholder Alert: Ademi LLP investigates Disclosure Issues involving ARCA biopharma, Inc.'s Transaction with Oruka

MILWAUKEE , June 4, 2024 /PRNewswire/ -- Ademi LLP is investigating ARCA (NASDAQ: ABIO) for possible breaches of fiduciary duty and other violations of law in its transaction with Oruka. Click here to learn how to join the https://www.ademilaw.com/case/arca-biopharma-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates Disclosure Issues involving ARCA biopharma, Inc.'s Transaction with Oruka

3 Short-Squeeze Stocks Ready to Soar on Roaring Kitty Rally

Yesterday, the forgotten meme stocks of 2021 started picking up serious momentum. But unlike 2021, it didn't take much to see the reason behind GameStop's (NYSE: GME ) sudden surge.

3 Short-Squeeze Stocks Ready to Soar on Roaring Kitty Rally

ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of ARCA biopharma, Inc. (the “Company”) (NasdaqCM: ABIO) and Oruka Therapeutics. Upon closing of the proposed transaction, ARCA shareholders are expected to own approximately 2.38% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, and whether th.

ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

ARCA biopharma and Oruka Therapeutics announce Merger Agreement ARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update.

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of ARCA Biopharma, Inc. - ABIO

NEW YORK , April 9, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating ARCA Biopharma, Inc. (Nasdaq: ABIO), relating to its proposed merger to Oruka Therapeutics.

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of ARCA Biopharma, Inc. - ABIO

See News Rankings

Charts implemented using Lightweight Charts™